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Abstract
Abacavir hypersensitivity syndrome (ABC HSS) is strongly associated with carriage of human 
leukocyte antigen (HLA)-B*57:01, which has a 100% negative predictive value for the 
development of ABC HSS. However, 45% of individuals who carry HLA-B*57:01 can tolerate 
ABC. We investigated immune and non-immune related genes in ABC HSS (n=95) and ABC 
tolerant (n=43) HLA-B*57:01+ patients to determine other factors required for the development of 
ABC HSS. Assignment of phenotype showed that ABC HSS subjects were significantly less likely 
than tolerants to carry only ERAP1 hypoactive trimming allotypes (p=0.02). An altered self-
peptide repertoire model by which abacavir activates T cells is in keeping with observation that 
endoplasmic reticulum aminopeptidase 1 (ERAP1) allotypes that favour efficient peptide trimming 
are more common in ABC HSS patients compared to patients who tolerate ABC. Independently, 
non-specific immune activation via soluble cluster of differentiation antigen 14 (sCD14) may also 
influence susceptibility to ABC HSS.
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1. Introduction
Abacavir (ABC) is an antiretroviral drug used to treat HIV infection and abacavir 
hypersensitivity syndrome (ABC HSS) is a model example of a severe, human leukocyte 
antigen (HLA)-associated, immune-mediated adverse drug reaction (IM-ADR)[1–3]. From 
studies examining patch test (PT) confirmed cases[3], ABC HSS develops within 36 hours-3 
weeks of therapy initiation and is characterized by initial fever, malaise, and systemic 
features with the development of mild to moderate rash in 70% of cases. Although patients 
recover within 48–72 hours upon withdrawal of the drug, a severe shock-like syndrome 
occurs on re-exposure. True immune-mediated ABC HSS only occurs in individuals who 
carry the HLA-B*57:01 allele, and not the related HLA-B17 serotype alleles (HLA-B*58:01 
and HLA-B*57:03). Clinical practice guidelines recommending screening for HLA-B*57:01 
before the initiation of ABC therapy has now been widely implemented in the developed 
world.
The PREDICT-1 study, which randomized patients to real-time HLA-B*57:01 screening 
versus ABC treatment without screening, supported a 100% negative predictive value 
(NPV), however it also showed that only 55% of those carrying HLA-B*57:01 developed 
ABC HSS[3]. These results demonstrate that HLA-B*57:01 is necessary for the 
development of ABC HSS but it is still unclear why 45% of those carrying HLA-B*57:01 
appear ABC tolerant[3] and what specific factors drive the incomplete positive predictive 
value (PPV). Based on peptide elution data and the crystal structure of ABC bound to HLA-
B*57:01, we[4] and others[5] have provided evidence for the altered peptide repertoire 
model of ABC HSS where non-covalent binding of ABC within the HLA-B*57:01 antigen 
blinding cleft alters the normal presentation of self-peptides. Accordingly, variations in 
molecules that are involved in antigen presentation, immune-related functions directly 
involving, or genetically linked, to HLA-B*57:01 or metabolism of ABC are likely 
candidates that contribute to ABC HSS susceptibility. Understanding the additional factors 
that contribute to ABC HSS may provide further clues into the immune-mechanisms of 
other IM-ADRs[6].
We conducted a retrospective genetic analysis of (PT+) ABC HSS and ABC tolerant HLA-
B*57:01 patients to investigate other immune- and drug-related factors in addition to HLA-
B*57:01 that contribute to ABC HSS susceptibility. The genes examined were: immune-
related major histocompatibility complex (MHC) genes in linkage disequilibrium (LD) with 
HLA-B; alcohol dehydrogenase (ADH) that metabolises ABC; innate immune system genes 
cluster of differentiation antigen 14 (CD14); natural killer (NK) cell killer-cell 
immunoglobulin-like receptors (KIR) KIR3DS1 and KIR3DL1 that are known ligands for 
HLA-B*57:01; and endoplasmic reticulum aminopeptidase 1 (ERAP1) and ERAP2 that trim 
the N-terminal of peptides before presentation on HLA class I molecules. All candidate gene 
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HLA-B*57:01+ patients who were either PT+ ABC HSS (using described techniques with 
1% and 10% abacavir; [7]) or ABC tolerant for >6 weeks with no symptoms and who had 
previously consented to genetic testing were identified from multicentre studies: The 
Prospective Randomized Evaluation of DNA Screening in a Clinical Trial (PREDICT-1; 
CNA106030), a randomized controlled double blinded study (n=42); the Study of 
Hypersensitivity to Abacavir and Pharmacogenetic Evaluation (SHAPE; ABC107442), a 
case control study (n=57); a multinational collaborative retrospective Canadian-Swiss-
Australian study; and a single HLA-B*57:01 ABC tolerant patient from the ACTG NWCS 
365 (n=39). In total there were n=95 PT+ ABC HSS and n=43 ABC tolerant patients.
For ERAP genotyping a subset of patients (n=56, PT+ ABC HSS; n=28, ABC tolerant; 
restricted to European ancestry) were available from the SHAPE and PREDICT studies. 
Genetic mapping for alleles of the HLA-B*57:01 extended MHC haplotype (also termed 
57.1 ancestral haplotype) was carried-out on patients from all three studies with high-
resolution HLA typing results available from the PREDICT-1 and multinational 
collaborative studies. Genotyping for ADH isoforms, KIR and CD14 was carried-out on 
patients with samples available from all three studies.
Ethics approval for this work was provided by the Royal Perth Hospital (2010/135), 
Murdoch University (2014/020) and Vanderbilt University Medical Center (IRB#131836) 
Human Research Ethics Committees and from the original PREDICT-1, SHAPE and 
multinational studies.
2.2 Genotyping
Four-digit HLA genotyping was conducted as previously described[3]. Sequence-based 
typing was used for the TNF single nucleotide polymorphisms (SNPs) −238 (rs361525) and 
−376 (rs1800750) (forward primer 5’-ACACAGGCCTCAGGACTCAA-3’, reverse primer 
5’- AACCAGCGGAAAACTTCCTT-3’). PCR sequence specific primer (PCR-SSP) assays 
were used to detect non-synonymous SNPs for loci on the HLA-B*57.1 extended MHC 
haplotype: HCP5 gene (rs2395029), BAT1–223 (rs2239527), HSP70Hom 493T[8], C4A*6 
and MICA*017. PCR-SSP was also used for the presence/absence of KIR3DS1/KIR3DL1 
and type 1 ADH isoforms 1B (rs1229984) and 1C (rs698) (see Table S1 for PCR-SSP 
primer details). A restriction fragment length polymorphism approach was used to detect a 
functional polymorphism in the promoter region of the CD14 gene [−159C/T]. Sequence-
based typing was used to determine the genotype of SNPs that characterise ERAP1 allotypes 
and rs2248374, a tag SNP for functional ERAP2 haplotypes[9].
PAVLOS et al. Page 3













2.3 ERAP trimming assignments
The amino acid (aa) positions relevant to impute ERAP1 allotype based on Reeves et al 
2013[10] (spanning the five residues M349V, K528R, D575N, R725Q and Q730E; as 
indicated in Figure 1B) and Ombrello et al 2015 (12 aa positions overall) were used to 
assign putative ERAP1 trimming efficiency as efficient, hyperactive or hypoactive. The 
novel combination (M349/K528/D575/R725/E730) was assigned an efficient trimming 
phenotype based on the wildtype amino acid at position 528.
2.4 Statistics
Pooled statistical analyses comparing genetic markers between the PT+ ABC HSS and ABC 
tolerant groups were carried-out using Fisher’s exact test. A p value <0.05 was set as a 
significance threshold. Multiple case-control/logistic regressions were performed to 
ascertain independent associations. Due to the small numbers in this study correction for 
multiple comparisons was not performed. Furthermore, the introduction of HLA-B*57:01 
screening before prescribing ABC now prevents the ability to obtain more samples for 
further analysis. Minor Allele Frequencies (MAF) were taken from the 1000 genomes 
project database (http://www.internationalgenome.org/data/). Assessment of LD and 
allocation of ERAP1 haplotypes was performed using the program Arlequin v3.5.2.2[11].
3. Results
No trend was observed between PT+ ABC HSS and ABC tolerant HLA-B*57:01 carriers for 
the haplospecific/typic markers MICA*017, HCP5, Bat-1, TNF, and Hsp70Hom present on 
the HLA-B*57.1 extended MHC haplotype. Although the presence of HLA-B*57:01 is 
necessary for ABC HSS, 45% patients carry HLA-B*57:01 but do not develop ABC HSS. 
This implies that factors in addition to HLA-B*57:01 but outside of the extended 57.1 
haplotype may contribute to the development of ABC HSS (Figure S1). There was also no 
difference in the presence of other genes known to interact with HLA-B*57:01 such as 
KIR3DS1/KIR3DL1, or polymorphisms in enzymes that metabolize ABC such as ADH 1B 
or ADH 1C. In multivariate models incorporating all three studies only the presence of 
C4A*6 and a functional polymorphism in the promoter of the CD14 gene [−159C/T] were 
significantly associated with the presence of PT+ ABC HSS (Table 1). We did not observe a 
trend between African and European ethnicity for any of the markers shown or between the 
ABC tolerant and PT+ ABC HSS patients (Table S2).
The presence of markers for the HLA-B*57:01 extended MHC haplotype was mapped for 
each of the subjects. Ancestral recombination events broke-down the haplotype in many 
individuals (e.g. 14/43 ABC tolerant subjects did not carry the full haplotype from C4A*6 to 
HLA-B*57:01) and a PT+ ABC HSS subject only carried HLA-B*57:01 confirming that 
HLA-B*57:01 is necessary. However, we have previously shown that only 55% of those 
carrying HLA-B*57:01 developed ABC HSS making it necessary but not sufficient for the 
development of ABC HSS. These results suggest these haplotype markers, although in LD 
with HLA-B*57:01, cannot be used as a surrogate for HLA-B*57:01 genetic screening or 
predictors of ABC HSS (Figure S1) and that genes outside of the MHC haplotype such as 
ERAP might contribute to the remaining positive predictive value.
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ERAP1 and ERAP2 variations were examined in an available subset of the PT+ ABC HSS 
(n=56) and ABC tolerant patients (n=28). A panel of SNPs were selected based on 
previously published ERAP1 allotypes[12] and analysis was restricted to European samples 
given the MAF differences observed between different ethnic groups for ERAP[13]. The 
SNPs rs2287987 (M349V), rs10050860 (D575N) and rs17482078 (R725Q) that encode 
amino acid changes in functional regions of ERAP showed significant LD (p<0.05). The 
differences in the carriage of the minor alleles for ERAP1 SNPs between PT+ ABC HSS 
and ABC tolerant patients were not significant. No significance differences were observed 
for ERAP2 rs2248374 comparing HLA-B*57:01 PT+ ABC HSS and ABC tolerant patients. 
A trend was observed for the SNP rs30187 (R528K) in the MAF for PT+ ABC HSS samples 
compared to ABC tolerant subjects and showed a significant difference compared to the 
reported MAFs in Europeans (based on the 1000 Genomes consortium; Table 2).
Although individual ERAP SNPs did not show significance when comparing the frequency 
in PT+ ABC HSS and ABC tolerant patients, it is known that ERAP function is dependent 
on haplotypes, rather than discrete variants[10]. Amino acid positions relevant for imputing 
ERAP1 allotype were used to assign putative ERAP1 trimming efficiency as efficient, 
hyperactive or hypoactive[10]. Given the assignments, ABC tolerant subjects were more 
likely to carry only hypoactive allotypes than PT+ ABC HSS subjects (p=0.02, Fisher’s 
exact test; Figure 1).
4. Discussion
Previous studies support that HLA-B*57:01 has a 100% negative predictive value for ABC 
HSS and therefore is necessary for its development. Our data reinforce this and suggest that 
in reference to the 45% of those carrying HLA-B*57:01 who tolerate ABC there is no one 
haplospecific marker in LD with HLA-B*57:01 that is associated with ABC 
tolerance(Figure S1). There was a signficant association between PT+ ABC HSS and CD14 
[−159C/T], located within the promoter region of CD14. CD14 is a co-receptor expressed by 
macrophages, neutorphils and dendritic cells that recognizes pathogen-associated molecular 
patterns and is the receptor for lipopolysaccharide. The CD14 −159 T variant is associated 
with increased levels of soluable CD14 (sCD14)[14]. sCD14 levels are predictive of 
increased mortality rates in treated HIV-infected individuals, independent of T cell count and 
most striking in individuals with advanced immunodeficiency[15, 16]. The link between 
sCD14 and HIV patient mortality is thought to reflect a compromised gut epithelial barrier. 
sCD14 is elevated in other diseases characterized or exacerbated by endotoxemia, such as 
hepatitis, rheumatoid arthritis, and systemic lupus erythematosus[15]. It is intriguing that 
CD14 variants, which reflect increased sCD14, are also significant in ABC HSS PT+ 
patients given that gastrointestinal symptoms are characteristic of the syndrome. This 
suggests that additional patient characteristics relating to HIV progression and gut 
endotoxemia in particular, could confer increased risk to ABC HSS in HLA-B57:01+ 
patients.
In addition to CD14 variation, ERAP1 functional haplotypes also displayed significant 
differences when comparing PT+ ABC HSS and ABC Tolerant HLA-B*57:01 patients. 
Epistatic interactions with ERAP1 have been described in autoimmune conditions such as 
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ankylosing spondylitis[12], birdshot retinopathy[17] and Behcet’s disease[18] with strong 
HLA associations with HLA-B*27:05, HLA-A*29:02 and HLA-B*51:01, respectively. In 
these diseases ERAP1 allotypes are known to affect the peptidomes for the risk HLA 
alleles[19–21]. The C-terminal of the bound peptide influences ERAP1 activity at the N-
terminal with a strong preference for peptides with hydrophobic or aromatic C-terminal 
residues (W, Y, F, M, A, V, L, or I, in order of the rate of N terminal trimming)[22]. 
Intriguingly, treatment of cells with ABC alters the peptide preference of HLA-B*57:01 at 
the C-terminal, favouring V and L over W and F [4] and therefore favouring peptides with 
C-terminal amino acids that promote the fastest rates of ERAP1-mediated peptide trimming. 
Consistent with this, our data predicts that ABC tolerant subjects tend to have hypoactive 
trimming ERAP1 allotypes. ABC is shown to bind within the F pocket of the peptide-
binding groove of HLA-B*57:01, and thus altering the repertoire of self-peptides presented 
to T cells [4]. The potential for ERAP1 to influence the repertoire of peptides available to be 
presented to T cells in the presence of ABC is in keeping with the primary hypothesis of the 
altered peptide model by which ABC causes HSS.
This work highlights the complexity of ABC HSS and ABC tolerance in HLA-B*57:01 
carriers. ABC HSS as a model of HLA-B*57:01 restricted HLA-mediated drug 
hypersentivity may universally depend on the ability to generate an altered repertoire of 
peptides presented to T cells by HLA-B*57:01 and may also be influenced independently by 
other innate factors such as sCD14 levels and the state of the gut epithelial barrier in HIV 
patients on therapy.
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ERAP1 allotypes. A. Schematic representation of ERAP1 with domains and active site 
indicated (bar). Amino acid positions relevant for the ERAP1 allotype nomenclature based 
on Reeves et al 2013 (red text)[10] and Ombrello et al 2015 (all sites)[13] indicated. B. 
Allotype frequency for the PT+ ABC HSS and ABC tolerant groups. The allotype defined 
by the MKDRE combination for the five defining SNPs has unknown phenotype, while the 
allotype defined as M349V/K528R also has D575N, R725Q and Q730E SNPs. p=0.02, 
Fisher’s exact test for carriage of efficient ERAP1 allotype between PT+ ABC HSS and 
ABC tolerant. Frequency of homozygous hypoactive ERAP in PT+ ABC HSS was 0.18 
compared to 0.43 in ABC tolerant group. Note ERAP1 combinations not described 
elsewhere were assigned the ‘efficient’ allotype based on wildtype amino acid at 349 and 
528. Note not all subjects had full typing across all SNPs; in three cases the allotype V349/
R528 was imputed given no typing at position 575.
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Table 1.
Genotype data for select genes in PT+ ABC HSS and ABC tolerant patients.





57.1 ancestral haplotype markers
C4A*6 79 (83) 26 (65) 0.03
Hsp70Hom 493T
CC 11 (11.6) 5 (12.5) 0.23
CT 73 (76.8) 26 (65)
TT 11 (11.6) 9 (22.5)
TNF-238
AA 3 (3.2) 1 (2.5) 0.76
GA 85 (89.5) 38 (95)
GG 7 (7.37) 1 (2.5)
TNF-376
GA 1 (1.1) 1 (2.5) 0.51
GG 94 (98.9) 39 (97.5)
BAT1–223
AA 2 (2.1) 0 0.41
AC 85 (89.5) 39 (97.5)
CC 8 (8.4) 1 (2.5)
HCP5(rs2395029)
GG 2 (2.1) 0 1
GT 92 (96.8) 40 (100)
TT 1 (1.1) 0
MICA*017 89 (98.9) 38 (100) 1
Abacavir Metabolism
ADH 1C (rs 698)
AA 30 (37) 15 (46.9) 0.59
GA 33 (40.7) 12 (37.5)
GG 18 (22.2) 5 (15.6)
ADH 1B (rs 1229984)
AA 1 (1.25) 0 1
GA 10 (12.5) 4 (12.5)
GG 69 (86.3) 28 (87.5)
Innate immune Genes
CD14 [159 C/T]
CC 18 (20.2) 16 (42.1) 0.025
CT 51 (57.3) 13 (34.2)
TT 20 (22.5) 9 (28.1)
KIR3DS1+ 44 (49.4) 17 (44.7) 0.70
KIR3DL1+ 85 (95.5) 37 (97.4) 1
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